Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Zimislecel · VX-880

Cell therapy (Stem-cell derived) · Cell replacement · developed by VERTEX PHARMACEUTICALS INC / MA

Phase 3 Most advanced trial

VRTX Developer

1 Registered trials

What is Zimislecel?

Zimislecel is an allogeneic stem cell-derived pancreatic islet cell therapy infused into the hepatic portal vein. It replaces destroyed islet cells in type 1 diabetes, restoring insulin production and blood glucose regulation. It is studied in type 1 diabetes with severe hypoglycemia and impaired hypoglycemic awareness.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: VX-880, Formerly known as STx-02
Drug type: Cell therapy (Stem-cell derived)
Mechanism: Cell replacement
Pathways: insulin production, glucose regulation
Therapy area: Endocrine
Developer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: 4FBM3KR723

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04786262	Phase 3	Diabetes Mellitus, Type 1	Recruiting	VRTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetes Mellitus, Type 1Impaired Hypoglycemic AwarenessSevere Hypoglycemia

More from VERTEX PHARMACEUTICALS INC / MA

Deutivacaftor FDA approved Elexacaftor FDA approved Exagamglogene Autotemcel FDA approved Ivacaftor FDA approved Suzetrigine FDA approved Tezacaftor FDA approved Vanzacaftor FDA approved Inaxaplin Phase 2/3 Povetacicept Phase 2/3 VX-017 Phase 3 VX-118 Phase 1 VX-264 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the VRTX page.

Follow VRTX, the company behind Zimislecel

See VRTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VRTX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z